Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo

Blood

Volumn 102, Issue 13, 2003, Pages 4472-4478

  Gomez, Gregorio ^a   Sitkovsky, Michail V ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ALANINE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; CONCANAVALIN A; INOSINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MECHANISM; ENDOTOXEMIA; ESCHERICHIA COLI; HEPATITIS; HISTOPATHOLOGY; IMMUNOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; TISSUE INJURY;

EID: 0344305461     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3624     Document Type: Article

References (53)

1. Tarkowski A, Wagner H. Arthritis and sepsis caused by Staphylococcus aureus: can the tissue injury be reduced by modulating the host's immune system? Mol Med Today. 1998;4:15-18.
2. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612-619.
3. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916-920.
4. Parmely MJ, Zhou W-W, Edwards CK, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol. 1993;151:389-396.
5. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur J Pharmacol. 1998;358:261-268.
6. Szabo C, Scott GS, Virag L, et al. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol. 1998;125:379-387.
7. Cronstein B. The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Br J Rheumatol. 1995;34:30-32.
8. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
9. Marabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;2:295-300.
10. Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine at inflamed sites. J Immunol. 1996;5:1937-1941.
11. Barankiewicz J, Cohen A. Purine nucleotide metabolism in resident and activated rat macrophages in vitro. Eur J Immunol. 1985;15:627-631.
12. Jabs CM, Neglen P, Eklof B. Breakdown of adenine nucleotides, formation of oxygen free radicals, and early markers of cellular injury in endotoxic shock. Eur J Surg. 1995;161:147-155.
13. Wang T, Sodhi J, Mentzer RMJ, Van Wylen DG. Changes in interstitial adenosine during hypoxia: relationship to oxygen supply:demand imbalance, and effects of adenosine deaminase. Cardiovasc Res. 1994;28:1320-1325.
14. Juhasz-Nagy A, Aviado DM. Inosine as a cardiotonic agent that reverses adrenergic beta blockade. J Pharmacol Exp Ther. 1977;202:683-695.
15. Hellewell PG, Pearson JD. Metabolism of circulating adenosine by the porcine isolated perfused lung. Circ Res. 1983;53:1-7.
16. Jones CE, Thomas JX, Devous MD, Norris CP, Smith EE. Positive ionotropic response to inosine in the in situ canine heart. Am J Physiol. 1977;233:H438-H443.
17. Rodriques-Nunez A, Cid E, Rodriguez-Garcia J, Camina F, Rodriguez-Segade S, Castro-Gago M. Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrospinal fluid of children with sepsis. J Child Neurol. 2001;16:704-706.
18. Schmidt H, Siems WG, Grune T, Grauel EL. Concentration of purine compounds in the cerebrospinal fluid of infants suffering from sepsis, convulsions and hydrocephalus. J Perinat Med. 1995;23:167-174.
19. Hasko G, Kuhel DG, Nemeth ZH, et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol. 2000;164:1013-1019.
20. Soriano FG, Liaudet L, Marton A, et al. Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med. 2001;29:703-708.
21. Liaudet L, Mabley JG, Soriano FG, et al. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med. 2001;164:1213-1220.
22. Liaudet L, Mabley JG, Pacher P, et al. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg. 2002;235:568-578.
23. Wakai A, Winter DC, Street JT, O'Sullivan RG, Wang JH, Redmond HP. Inosine attenuates tourniquet-induced skeletal muscle reperfusion injury. J Surg Res. 2001;99:311-315.
24. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler. 2001;7:313-319.
25. Cheng Y, Jiang DH. Therapeutic effect of inosine in Tourette syndrome and its possible mechanism of action. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1990;23:90-93, 126-127.
26. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest. 1997;100:2849-2857.
27. Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, Koller BH. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. J Clin Invest. 2000;105:361-367.
28. Tiegs G, Hentschel J, Wendel A. A T-cell dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. 1992;90:196-203.
29. Tiegs G. Experimental hepatitis and role of cytokines. Acta Gastroenterol Belg. 1997;60:176-179.
30. Kaneko Y, Harada M, Kawano T, et al. Augmentation of Valpha14 NK T cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med. 2000;191:105-114.
31. Takeda K, Hayakawa Y, Kaer LV, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97:5498-5503.
32. Nakamura K, Okada M, Yoneda M, et al. Macrophage inflammatory protein-2 induced by TNF-α plays a pivotal role in concanavalin A-induced liver injury in mice. J Hepatol. 2001;35:217-224.
33. Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology. 1996;111:462-471.
34. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology. 1995;21:190-198.
35. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 2000;11:219-232.
36. Hoshino K, Takeuchi O, Kawai T, et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749-3752.
37. Reid RR, Prodeus AP, Khan W, Hsu T, Rosen FS, Carroll MC. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol. 1997;159:970-975.
38. Chen J-F, Huang Z, Ma J, et al. A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci. 1999;19:9192-9200.
39. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem. 2000;275:4429-4434.
40. Marco RD, Xiang M, Zaccone P, et al. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity. 1999;31:75-83.
41. Louis H, Moine OL, Peny M-O, et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology. 1997;25:1382-1389.
42. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol. 1994;153:4159-4168.
43. McWhinney CD, Dudley MW, Bowlin TL, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-α. Eur J Pharmcol. 1996;310:209-216.
44. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996;156:3435-3442.
45. Link AA, Kino T, Worth JA, et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol. 2000;164:436-442.
46. Hasko G, Kuhel DG, Chen J-F, et al. Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 2000;14:2065-2074.
47. Suzuki H, Takei M, Nakahata T, Fukamachi H. Inhibitory effect of adenosine on degranulation of human cultured mast cells upon cross-linking of FcεRI. Bichem Biophys Res Comm. 1998;242:697-702.
48. Smith SR, Denhardt G, Terminelli C. A role for histamine in cytokine modulation by the adenosine A3 receptor agonist, 2-CI-IB-MECA. Eur J Pharm. 2002;457:57-69.
49. Smiseth OA. Inosine infusion in dogs with acute ischaemic left ventricular failure: favourable effects on myocardial performance and metabolism. Cardiovasc Res. 1983;17:192-199.
50. Benowitz LI, Goldberg DE, Madsen JR, Suni D, Irwin N. Inosine stimulates extensive axon collateral growth in the rat corticospinal tract after injury. Proc Natl Acad Sci U S A 1999;96:13486-13490.
51. Chen P, Goldberg DE, Kolb B, Lanser M, Benowit LI. Inosine induces axonal rewiring and improves behavioral outcome after stroke. Proc Natl Acad Sci U S A 2002;99:9031-9036.
52. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002;99:16303-16308.
53. Harada N, Okajima K, Murakami K, et al. Adenosine and selective A2a receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther. 2000;294:1034-1042.